Tabula Rasa HealthCare (TRHC) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Tabula Rasa HealthCare (NASDAQ: TRHC):

  • 5/30/2019 – Tabula Rasa HealthCare was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “
  • 5/23/2019 – Tabula Rasa HealthCare was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “
  • 5/15/2019 – Tabula Rasa HealthCare was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “
  • 5/13/2019 – Tabula Rasa HealthCare was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 5/13/2019 – Tabula Rasa HealthCare had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $99.00 price target on the stock. They wrote, “. We reiterate our Overweight rating on TRHC shares and maintain our 12-month price target at $99. Rasa reported 1Q19 results, which appeared to be strong. We note that the company posted strong organic growth of 19%. Adjusted EBITDA was above our estimate and the company reaffirmed its 2019 guidance for revenue and adjusted EBITDA. Our EPS estimates moved lower to reflect the higher interest expense given the 1Q19 convert. While the company has executed in the short term, we suspect that investors are more concerned about the number of acquisitions the company has completed in the last two years and its integration efforts.””
  • 5/9/2019 – Tabula Rasa HealthCare had its price target raised by analysts at Piper Jaffray Companies from $73.00 to $78.00. They now have an “overweight” rating on the stock.
  • 5/8/2019 – Tabula Rasa HealthCare was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “
  • 5/7/2019 – Tabula Rasa HealthCare was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 5/2/2019 – Tabula Rasa HealthCare was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $61.00 price target on the stock. According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “
  • 4/30/2019 – Tabula Rasa HealthCare was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 4/23/2019 – Tabula Rasa HealthCare was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 4/17/2019 – Tabula Rasa HealthCare is now covered by analysts at Guggenheim. They set a “neutral” rating and a $58.00 price target on the stock.

Tabula Rasa HealthCare stock traded down $0.77 during mid-day trading on Monday, reaching $44.40. 4,941 shares of the stock traded hands, compared to its average volume of 335,878. The stock has a market cap of $993.21 million, a PE ratio of 130.59 and a beta of 1.68. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.73 and a current ratio of 1.80. Tabula Rasa HealthCare Inc has a 12-month low of $42.29 and a 12-month high of $91.16.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) EPS for the quarter, meeting analysts’ consensus estimates of ($0.14). Tabula Rasa HealthCare had a positive return on equity of 4.22% and a negative net margin of 18.15%. The company had revenue of $60.96 million during the quarter, compared to analysts’ expectations of $59.24 million. As a group, sell-side analysts predict that Tabula Rasa HealthCare Inc will post -0.55 EPS for the current fiscal year.

In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,270 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $53.68, for a total transaction of $443,933.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $58.10, for a total value of $464,800.00. The disclosure for this sale can be found here. Insiders have sold 48,270 shares of company stock valued at $2,565,774 in the last three months. 14.00% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in TRHC. BlackRock Inc. boosted its stake in Tabula Rasa HealthCare by 1.8% during the first quarter. BlackRock Inc. now owns 2,647,485 shares of the company’s stock valued at $149,370,000 after buying an additional 46,601 shares during the last quarter. Vanguard Group Inc. raised its position in Tabula Rasa HealthCare by 6.9% during the third quarter. Vanguard Group Inc. now owns 967,769 shares of the company’s stock valued at $78,573,000 after purchasing an additional 62,267 shares during the period. Jennison Associates LLC raised its position in Tabula Rasa HealthCare by 17.2% during the first quarter. Jennison Associates LLC now owns 885,611 shares of the company’s stock valued at $49,966,000 after purchasing an additional 130,137 shares during the period. Macquarie Group Ltd. raised its position in Tabula Rasa HealthCare by 82.3% during the first quarter. Macquarie Group Ltd. now owns 576,248 shares of the company’s stock valued at $32,512,000 after purchasing an additional 260,208 shares during the period. Finally, M&T Bank Corp purchased a new stake in Tabula Rasa HealthCare during the fourth quarter valued at approximately $33,749,000. 86.66% of the stock is owned by institutional investors and hedge funds.

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Read More: Coverage Ratio

Receive News & Ratings for Tabula Rasa HealthCare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare Inc and related companies with MarketBeat.com's FREE daily email newsletter.